Skip to main content

Cerebral Aspergillosis

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Imagine Pharma
Imagine PharmaPA - Pittsburgh
1 program
European Study of Cerebral Aspergillosis Treated With IsavuconazoleN/ASmall Molecule1 trial
Active Trials
NCT04486885Completed41Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Imagine PharmaEuropean Study of Cerebral Aspergillosis Treated With Isavuconazole

Clinical Trials (1)

Total enrollment: 41 patients across 1 trials

NCT04486885Imagine PharmaEuropean Study of Cerebral Aspergillosis Treated With Isavuconazole

European Study of Cerebral Aspergillosis Treated With Isavuconazole

Start: Aug 2021Est. completion: Mar 202341 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.